Archives: Agenda

• The surge of high-quality assets from China: what’s driving the acceleration?
• Licensing trends: why Western pharma is increasingly looking East
• Regulatory implications: how the FDA and global bodies are adapting
• Geopolitics vs innovation: balancing risk, access, and opportunity in trial strategy

China’s life sciences sector is rapidly reshaping the global biotech landscape, with a growing pipeline of high-quality assets attracting significant international investment and licensing activity. This session will explore how this shift is impacting clinical development strategies, regulatory frameworks, and competitive dynamics. From navigating cross-border partnerships to understanding evolving FDA perspectives, join industry leaders as they unpack what this means for outsourcing, trial design, and the future of global collaboration.

Biotech companies often operate with lean teams and limited resources yet face the same complexities as larger pharma. This session will explore how smaller organisations can maximise internal capabilities, leverage cross-functional talent, and build efficient operating models to successfully deliver clinical trials.

• Making the most of lean teams: prioritisation and resource allocation strategies
• Leveraging cross-functional talent and transferable skillsets across departments
• Building agile operating models to increase efficiency and speed
• When to outsource vs keep capabilities in-house
• Empowering individuals to take on broader roles and responsibilities
• Creating a culture of collaboration and flexibility to drive delivery

• Navigating traditional and niche CRO models as an emerging biotech
• Understanding the key differences between big pharma and biotech approaches to clinical trial execution and outsourcing strategy
• Examining how niche and specialist vendors are addressing sponsor pain points with more tailored, flexible solutions
• Identifying how sponsors and providers can better align expectations, communication models, and operational support for successful partnerships

For biotech and emerging biopharma companies, every development decision carries significant implications for timelines, funding milestones, and investor confidence. As pressure mounts to advance programs faster, the most successful organizations are using predictive analytics, integrated development planning, and data-driven decision-making to de-risk clinical development and accelerate execution across the entire development lifecycle.

Join this session to learn how biotech sponsors can reduce uncertainty from first-in-human studies through pivotal trials by reducing delays between phases, increasing cross-functional coordination, and improving operational execution to bring therapies to patients faster.

Key Discussion Points:

• Accelerating transitions between Phase I, II, and III studies
• Reducing operational “white space” between development milestones
• Increasing parallelization of clinical, regulatory, and operational workstreams
• Improving enrollment forecasting and predictability
• Driving efficiency and speed across the end-to-end development lifecycle